Tolga Tanguler Sells 1,510 Shares of Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) EVP Tolga Tanguler sold 1,510 shares of the company’s stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $362.87, for a total transaction of $547,933.70. Following the completion of the transaction, the executive vice president owned 29,728 shares in the company, valued at approximately $10,787,399.36. This trade represents a 4.83% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY opened at $359.18 on Friday. The company has a debt-to-equity ratio of 4.45, a current ratio of 2.54 and a quick ratio of 2.49. The firm has a market cap of $47.45 billion, a PE ratio of 1,496.56 and a beta of 0.32. The firm has a 50 day simple moving average of $420.41 and a 200-day simple moving average of $421.12. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ALNY. Stifel Nicolaus raised their price target on Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the stock a “buy” rating in a research note on Thursday, December 11th. Royal Bank Of Canada increased their price objective on shares of Alnylam Pharmaceuticals from $435.00 to $500.00 and gave the stock an “outperform” rating in a report on Friday, September 19th. Jefferies Financial Group decreased their target price on shares of Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating on the stock in a research report on Thursday, October 30th. Wells Fargo & Company upped their price target on shares of Alnylam Pharmaceuticals from $395.00 to $479.00 and gave the stock an “equal weight” rating in a research report on Tuesday, November 11th. Finally, Morgan Stanley increased their price target on shares of Alnylam Pharmaceuticals from $405.00 to $475.00 and gave the stock an “equal weight” rating in a research note on Monday, October 6th. Twenty-two analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $490.96.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Alnylam Pharmaceuticals by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 13,565,452 shares of the biopharmaceutical company’s stock valued at $6,185,846,000 after purchasing an additional 268,313 shares in the last quarter. Capital Research Global Investors boosted its position in shares of Alnylam Pharmaceuticals by 0.4% in the third quarter. Capital Research Global Investors now owns 7,222,840 shares of the biopharmaceutical company’s stock worth $3,293,516,000 after buying an additional 31,184 shares during the period. Groupama Asset Managment grew its stake in shares of Alnylam Pharmaceuticals by 160.4% in the third quarter. Groupama Asset Managment now owns 4,032,082 shares of the biopharmaceutical company’s stock valued at $18,610,000 after buying an additional 2,483,697 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 3.3% during the 2nd quarter. Geode Capital Management LLC now owns 2,398,770 shares of the biopharmaceutical company’s stock valued at $779,857,000 after buying an additional 75,936 shares during the period. Finally, Orbis Allan Gray Ltd lifted its position in Alnylam Pharmaceuticals by 29.8% during the 2nd quarter. Orbis Allan Gray Ltd now owns 2,121,412 shares of the biopharmaceutical company’s stock worth $691,771,000 after acquiring an additional 486,489 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Alnylam Pharmaceuticals News Roundup

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Analysts maintain a generally constructive stance: ALNY carries a consensus “Moderate Buy” from sell‑side firms, supporting a bullish medium‑term view for the shares. Alnylam Pharmaceuticals, Inc. Receives Consensus Rating of “Moderate Buy” from Analysts
• Positive Sentiment: Needham published a bullish forecast, highlighting upside tied to Alnylam’s longer‑term (Alnylam 2030) growth plan — a catalyst that could support recovery if execution meets targets. Needham & Company LLC Forecasts Strong Price Appreciation for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock
• Neutral Sentiment: Context/valuation pieces are circulating that reassess ALNY’s premium valuation versus the newly unveiled Alnylam 2030 plan — useful for investors weighing long‑range upside against current multiples. A Look At Alnylam Pharmaceuticals (ALNY) Valuation After Unveiling Its Alnylam 2030 Growth Plan
• Neutral Sentiment: Analyst opinions are mixed across the healthcare coverage universe, with some firms trimming targets while others remain upbeat — this divergence contributes to higher intraday volatility. Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY) …
• Negative Sentiment: Concentrated insider selling: multiple senior executives — including CEO Yvonne Greenstreet and several EVPs — disclosed sizable share sales on Jan. 12–13 (individual sales in the $0.5M–$3.5M range), which typically increases near‑term sell pressure and raises investor caution. Alnylam Insiders Quietly Unload a Major Chunk of Stock in Synchronized Sell‑Off
• Negative Sentiment: Market reaction to the company’s ambitious 2026 guidance and the Alnylam 2030 plan was negative — coverage noted a sharp intraday slide after the announcement — and Bank of America issued a pessimistic forecast that may amplify selling pressure. Alnylam Pharmaceuticals (ALNY) Is Down 9.0% After Ambitious 2026 Guidance And 2030 Plan Reveal
• Negative Sentiment: Bank of America lowered its outlook and flagged downside risk, adding to analyst‑driven selling pressure following the company’s strategic/guidance update. Bank of America Issues Pessimistic Forecast for Alnylam Pharmaceuticals (NASDAQ:ALNY) Stock Price

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.